INCR vs. YMAB, VYGR, LFVN, ITOS, AQST, IMMP, NGNE, OLMA, ATYR, and RZLT
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Immutep (IMMP), Neurogene (NGNE), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.
InterCure vs.
Y-mAbs Therapeutics (NASDAQ:YMAB) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
InterCure has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. InterCure's return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.
70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 22.5% of Y-mAbs Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Y-mAbs Therapeutics and Y-mAbs Therapeutics both had 2 articles in the media. Y-mAbs Therapeutics' average media sentiment score of 0.16 beat InterCure's score of -0.33 indicating that Y-mAbs Therapeutics is being referred to more favorably in the media.
Y-mAbs Therapeutics received 132 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 63.38% of users gave Y-mAbs Therapeutics an outperform vote.
Y-mAbs Therapeutics currently has a consensus target price of $20.89, suggesting a potential upside of 239.11%. Given Y-mAbs Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than InterCure.
InterCure has higher revenue and earnings than Y-mAbs Therapeutics.
Y-mAbs Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
Summary
Y-mAbs Therapeutics beats InterCure on 9 of the 16 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
This page (NASDAQ:INCR) was last updated on 1/21/2025 by MarketBeat.com Staff
